\boolfalse {citerequest}\boolfalse {citetracker}\boolfalse {pagetracker}\boolfalse {backtracker}\relax 
\babel@toc {english}{}
\contentsline {chapter}{Summary}{i}{chapter*.1}%
\contentsline {chapter}{Zusammenfassung}{iii}{chapter*.2}%
\contentsline {section}{\numberline {0.1}maybe fun to add.}{1}{section.0.1}%
\contentsline {chapter}{\chapternumberline {1}introduction}{3}{chapter.1}%
\contentsline {subsection}{Treatment Strategies}{4}{section*.6}%
\contentsline {subsection}{Population Dynamics under Combination Therapy}{5}{section*.7}%
\contentsline {section}{\numberline {1.1}Thesis outline}{6}{section.1.1}%
\contentsline {chapter}{\chapternumberline {2}The Impact of Treatment Strategies on the Epidemiological Dynamics of Plasmid-Conferred Antibiotic Resistance}{11}{chapter.2}%
\contentsline {section}{\numberline {2.1}abstract}{11}{section.2.1}%
\contentsline {section}{\numberline {2.2}Introduction}{11}{section.2.2}%
\contentsline {section}{\numberline {2.3}Results}{14}{section.2.3}%
\contentsline {paragraph}{Multidrug strategies keep the overall number of infections lowest and best suppress single resistance.}{14}{section*.11}%
\contentsline {paragraph}{All treatment strategies fail to contain pre-existing double resistance.}{17}{section*.13}%
\contentsline {paragraph}{Treatment strategies affect the emergence of double resistance.}{17}{section*.14}%
\contentsline {paragraph}{Combination therapy suppresses the emergence of double resistance by preventing superinfections.}{18}{section*.15}%
\contentsline {paragraph}{Treatment strategies influence the emergence of double resistance within superinfected wells.}{18}{section*.16}%
\contentsline {paragraph}{Computational model corroborates the robustness of experimental outcomes.}{19}{section*.18}%
\contentsline {paragraph}{\textit {In silico} sensitivity analysis indicates that the superiority of combination therapy is robust.}{20}{section*.19}%
\contentsline {section}{\numberline {2.4}Discussion}{21}{section.2.4}%
\contentsline {section}{\numberline {2.5}Methods}{25}{section.2.5}%
\contentsline {paragraph}{Drugs and Media.}{25}{section*.21}%
\contentsline {paragraph}{Strains and Plasmids.}{25}{section*.22}%
\contentsline {paragraph}{Treatment arms.}{25}{section*.23}%
\contentsline {paragraph}{Assay plates.}{25}{section*.24}%
\contentsline {paragraph}{Experimental procedure. }{26}{section*.25}%
\contentsline {paragraph}{Turnover.}{26}{section*.26}%
\contentsline {paragraph}{Infections.}{26}{section*.27}%
\contentsline {paragraph}{Resistance Profiles.}{27}{section*.28}%
\contentsline {paragraph}{Scenarios.}{27}{section*.29}%
\contentsline {paragraph}{Instruction Sets.}{28}{section*.30}%
\contentsline {paragraph}{Computational Model.}{28}{section*.31}%
\contentsline {paragraph}{\textit {In Silico} Sensitivity Analysis.}{28}{section*.32}%
\contentsline {paragraph}{Data Availability}{29}{section*.33}%
\contentsline {section}{\numberline {2.6}Supplementary Information Chapter 2}{31}{section.2.6}%
\contentsline {subsection}{SI Methods}{31}{section*.36}%
\contentsline {paragraph}{Strains}{31}{section*.37}%
\contentsline {paragraph}{Drugs.}{31}{section*.38}%
\contentsline {paragraph}{Conjugation Protocol.}{32}{section*.39}%
\contentsline {paragraph}{Plasmid costs}{32}{section*.40}%
\contentsline {paragraph}{Segregational Loss}{32}{section*.41}%
\contentsline {paragraph}{Growth rates and bacterial density.}{33}{section*.42}%
\contentsline {paragraph}{Basic Reproductive Number.}{33}{section*.43}%
\contentsline {paragraph}{Phenotyping -- Limitations. }{33}{section*.44}%
\contentsline {paragraph}{Advanced Resistance Profiles}{35}{section*.45}%
\contentsline {paragraph}{Statistical Analysis. }{35}{section*.46}%
\contentsline {paragraph}{\textit {Maximum-emergence}~scenario: Predicting the Emergence Probability.}{36}{section*.47}%
\contentsline {subsection}{SI Results}{37}{section*.48}%
\contentsline {paragraph}{Impact of Treatment on the Emergence of Double Resistance.}{37}{section*.49}%
\contentsline {paragraph}{Treatment strategies influence the number of bacteria inoculating superinfections. }{37}{section*.50}%
\contentsline {paragraph}{Antagonism.}{38}{section*.51}%
\contentsline {subsection}{SI Computational Model}{38}{section*.52}%
\contentsline {paragraph}{Stochasticity}{38}{section*.53}%
\contentsline {paragraph}{Transition Probabilities.}{39}{section*.54}%
\contentsline {paragraph}{Transition Probabilities for Transfer 1.}{39}{section*.55}%
\contentsline {paragraph}{Choice of Model.}{39}{section*.56}%
\contentsline {paragraph}{Contamination of the Transition Matrix. }{40}{section*.57}%
\contentsline {paragraph}{Filtered Transition Probabilities.}{41}{section*.58}%
\contentsline {chapter}{\chapternumberline {3}High-Throughput Quantification of Population Dynamics using Luminescence}{69}{chapter.3}%
\contentsline {section}{\numberline {3.1}abstract}{69}{section.3.1}%
\contentsline {section}{\numberline {3.2}Introduction}{69}{section.3.2}%
\contentsline {section}{\numberline {3.3}Results}{71}{section.3.3}%
\contentsline {paragraph}{Light intensity is proportional to bacterial density.}{73}{section*.111}%
\contentsline {paragraph}{Luminescence-based rates agree with CFU-based kill rates in 11 out of 22 antimicrobial assays.}{73}{section*.112}%
\contentsline {paragraph}{No support for SOS-driven increase in luminescence promoter activity.}{73}{section*.113}%
\contentsline {paragraph}{Filamentation aligns with divergence between CFU- and luminescence-based rates.}{74}{section*.114}%
\contentsline {paragraph}{Filamentation model predicts divergence between luminescence- and CFU-based rates.}{74}{section*.116}%
\contentsline {paragraph}{Adjusting luminescence intensities by changes in volume narrows the gap between CFU- and luminescence-based rates.}{76}{section*.117}%
\contentsline {paragraph}{CFU-based estimates can overestimate the rate of population decline.}{77}{section*.119}%
\contentsline {paragraph}{Partial loss of culturability causes CFU to underestimate \(\mitpsi _B\) for ciprofloxacin and trimethoprim treatment.}{79}{section*.120}%
\contentsline {paragraph}{Antimicrobial carryover causes underestimation of $\mitpsi _B$ for pexiganan using CFU.}{80}{section*.121}%
\contentsline {paragraph}{Luminescence and CFU show identical decline rates for pexiganan time-kill curves if residual killing is prevented.}{81}{section*.122}%
\contentsline {paragraph}{Pexiganan rapidly loses killing capacity.}{81}{section*.123}%
\contentsline {section}{\numberline {3.4}Discussion}{82}{section.3.4}%
\contentsline {section}{\numberline {3.5}Methods}{84}{section.3.5}%
\contentsline {paragraph}{Strains.}{84}{section*.124}%
\contentsline {paragraph}{Media.}{85}{section*.125}%
\contentsline {paragraph}{Automated CFU plating.}{85}{section*.126}%
\contentsline {paragraph}{Luminescence measurements.}{85}{section*.127}%
\contentsline {paragraph}{Luminescence-CFU assay setup.}{86}{section*.128}%
\contentsline {paragraph}{Rapid luminescence-CFU assay setup.}{86}{section*.129}%
\contentsline {paragraph}{Morphology experiments.}{86}{section*.130}%
\contentsline {paragraph}{Fitting rates of change $\mitpsi $.}{86}{section*.131}%
\contentsline {paragraph}{Significance.}{87}{section*.132}%
\contentsline {section}{\numberline {3.6}Supplementary Information Chapter 3}{90}{section.3.6}%
\contentsline {section}{\numberline {3.7}Mathematical descriptions}{90}{section.3.7}%
\contentsline {subsection}{Light-related terminology.}{90}{section*.136}%
\contentsline {subsection}{Testing for linearity between bacterial density and luminescent light intensity.}{90}{section*.137}%
\contentsline {subsection}{Rate of change of CFU count.}{91}{section*.138}%
\contentsline {subsection}{Rate of change of luminescence.}{92}{section*.139}%
\contentsline {subsection}{Rate of change of volume-corrected luminescence.}{93}{section*.140}%
\contentsline {subsection}{Change of light intensity is closer to the rate of change of total cell-volume than to the rate of change of number of bacteria.}{94}{section*.141}%
\contentsline {subsection}{Colony formation -- birth-death Markov Model.}{95}{section*.142}%
\contentsline {subsection}{Colony formation for bacteriostatic and bactericidal drugs.}{95}{section*.143}%
\contentsline {section}{\numberline {3.8}Filamentation Model}{96}{section.3.8}%
\contentsline {subsection}{Population‚Äêlevel quantities.}{98}{section*.144}%
\contentsline {subsection}{Parameter sensitivity.}{99}{section*.145}%
\contentsline {subsection}{Volume correction and parameter estimation}{99}{section*.146}%
\contentsline {section}{\numberline {3.9}Experiments}{100}{section.3.9}%
\contentsline {subsection}{SOS experiment.}{100}{section*.147}%
\contentsline {subsection}{Morphology evaluation.}{101}{section*.148}%
\contentsline {subsection}{Antimicrobial peptide deactivation experiment.}{102}{section*.149}%
\contentsline {subsection}{Manual pexiganan time-kill curve experiment.}{102}{section*.150}%
\contentsline {subsection}{Supernatant experiment.}{103}{section*.151}%
\contentsline {chapter}{\chapternumberline {4}Antimicrobial Combination Effects at Subinhibitory Doses do not Reliably Predict Effects at Inhibitory Concentrations}{139}{chapter.4}%
\contentsline {section}{\numberline {4.1}Introduction}{139}{section.4.1}%
\contentsline {section}{\numberline {4.2}Results}{141}{section.4.2}%
\contentsline {section}{\numberline {4.3}Discussion}{141}{section.4.3}%
\contentsline {section}{\numberline {4.4}Methods}{141}{section.4.4}%
\contentsline {section}{\numberline {4.5}Data, Materials, and Software Availability}{141}{section.4.5}%
\contentsline {section}{\numberline {4.6}Supplementary Information Chapter 4}{144}{section.4.6}%
\contentsline {section}{\numberline {4.7}SI TEXT}{145}{section.4.7}%
\contentsline {subsection}{Time weighted net growth rates}{145}{section*.201}%
\contentsline {subsection}{Quantifying Light Noise.}{147}{section*.202}%
\contentsline {subsection}{Drug conditions and response functions}{147}{section*.203}%
\contentsline {paragraph}{Single-drug pharmacodynamic curves.}{147}{section*.204}%
\contentsline {paragraph}{Closed-form inversion.}{147}{section*.205}%
\contentsline {paragraph}{Cartesian conditions.}{147}{section*.206}%
\contentsline {paragraph}{Polar pharmacodynamic curves.}{148}{section*.207}%
\contentsline {subsection}{Bliss independence}{148}{section*.208}%
\contentsline {paragraph}{Time--varying hazards.}{148}{section*.209}%
\contentsline {paragraph}{Bliss-based interaction index \(\mitmu \).}{148}{section*.210}%
\contentsline {subsection}{Loewe additivity}{149}{section*.211}%
\contentsline {paragraph}{Loewe interaction index (\(\mitnu \)).}{149}{section*.212}%
\contentsline {subsection}{Peptide--antibiotic interaction model}{151}{section*.213}%
\contentsline {subsection}{Condition-wise interaction inference on the checkerboard}{151}{section*.214}%
\contentsline {paragraph}{Regime-wise aggregation across checkerboard conditions.}{152}{section*.215}%
\contentsline {subsection}{Continuous interaction surfaces and geometric exploration}{153}{section*.216}%
\contentsline {paragraph}{Density-based restriction of the surface domain.}{153}{section*.217}%
\contentsline {paragraph}{Bootstrap datasets and coordinate transform.}{153}{section*.218}%
\contentsline {paragraph}{Monotone surface construction.}{153}{section*.219}%
\contentsline {paragraph}{Bliss and Loewe interaction indices on the surface.}{153}{section*.220}%
\contentsline {subsection}{Single-drug inoculum effect analysis}{154}{section*.221}%
\contentsline {section}{\numberline {4.8}SI tables}{156}{section.4.8}%
\contentsline {section}{\numberline {4.9}SI figures}{156}{section.4.9}%
\contentsline {chapter}{\chapternumberline {5}Concluding Remarks}{171}{chapter.5}%
\contentsline {section}{\numberline {5.1}Is combination therapy the best treatment strategy?}{171}{section.5.1}%
\contentsline {section}{\numberline {5.2}Can luminescence serve as a proxy for net growth?}{173}{section.5.2}%
\contentsline {section}{\numberline {5.3}Can interaction data from sub-MIC concentrations be extrapolated to the killing range?}{174}{section.5.3}%
\contentsline {section}{\numberline {5.4}General concluding note}{174}{section.5.4}%
